Summit Therapeutics plc announced the appointment of Dr. David Roblin as Chief Operating Officer (‘COO’) and President of Research and Development. In this new non-board role at Summit, Dr. Roblin will lead R&D and Commercial functions to support the development of the DMD and CDI programmes. Dr. Roblin, who has been acting as a research and development adviser to Summit since 2014, will take up his new role on an interim basis in April 2017 with this becoming full-time in June 2017. Dr. Roblin has had a highly successful career in the life sciences industry, including senior leadership roles at Pfizer and Bayer, which involved overseeing the research, development and commercial launch of drugs across several therapy areas including infectious diseases. Dr. Roblin’s most recent role was COO and Director of Scientific Translation at the Francis Crick Institute.